cervical carcinoma
Conditions
Interventions
Intervention group:Radiochemotherapy+Zhenqi Liujun Anti cancer Granule
Control group:Radiochemotherapy
Sponsors
The Traditional Chinese Medicine Hospital Affiliated to Southwest
Eligibility
Sex/Gender
Female
Age
18 Years to 75 Years
Inclusion criteria
Inclusion criteria: ? Cervical cancer definitely diagnosed by histology or pathology? Subjects did not receive any systematic anti-tumor treatment, such as chemotherapy, radiotherapy, immunotherapy, biological or hormone therapy, and did not receive any VEGFR inhibitor treatment in the past three months;? There was no operation or large biopsy within 4 weeks after randomization;? Age = 18 years and = 75 years, weight = 40Kg;? The subjects had no dysfunction of heart, liver, kidney and hematopoietic system; The definition is as follows: absolute neutrophil count (ANC)>1.5 × 109/L,; Platelets>100 × 109/L; Hemoglobin = 90g/L; Total bilirubin = 1.5 × Upper limit of normal (ULN); AST(SGOT)/ALT(SGPT)=2.5 × The upper limit of normality, if it is clearly attributable to liver metastasis, is less than 5 times the upper limit of normality; UPCR<1.0;? Physical condition score: ECOG 0~2, KPS = 50;? Estimated survival time = 12 weeks;? Fully understand the study and voluntarily sign the informed consent form.
Exclusion criteria
Exclusion criteria: 1. Prepare for tumor immunotherapy;2. Patients with unstable brain metastasis;3. Pregnant and lactating women and patients of childbearing age who are unwilling to take contraceptive measures;4. Patients with mental illness or mental retardation;5. Known to be severely intolerant of the study drug;6. Patients with serious diseases such as heart, liver, kidney and hematopoietic system (1. Absolute neutrophil count (ANC) 1.5 × Upper limit of normal (ULN); AST(SGOT)/ALT(SGPT)>2.5 × Normal upper limit, if it is clearly attributable to liver metastasis, = 5 times of normal upper limit; 3. Creatinine clearance rate 160mmHg or diastolic blood pressure>100mmHg after single drug treatment), severe arrhythmia, and cardiac function class III-IV (NYHA classification).
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Occurrence rate of radioactive inflammation;Degree of bone marrow suppression;T lymphocytes; | — |
Secondary
| Measure | Time frame |
|---|---|
| Quality of life;Adverse events; | — |
Countries
China
Contacts
Public ContactZhongming Yang
The Traditional Chinese Medicine Hospital Affiliated to Southwest
Outcome results
None listed